The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price. Do they really matter, though?Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about DexCom (DXCM) .DexCom currently has an average brokerage recommen ...

DexCom (DXCM) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.Over the past month, shares of this medical device company have returned -7.1%, compared to the Zacks S&P 500 composite's +5% change. During this period, the Zacks Medical - Instruments industry, which DexCom falls in, has gained 3.3%. The key question now is: What could be the stock's future direction?A ...

DexCom, Inc. (DXCM) reported fourth-quarter 2023 adjusted earnings per share (EPS) of 50 cents, which beat the Zacks Consensus Estimate of 43 cents by 16.3%. The company reported earnings of 34 cents per share in the prior-year quarter.DXCM registered GAAP net income per share of 62 cents, up from the year-ago quarter’s figure of 22 cents.Revenue DetailsTotal revenues grew 27% (26% on an organic basis) to $1.03 billion on a year-over-year basis and beat the Zacks Consensus Estimate by 0.4%. Strong revenue g ...

DexCom, Inc. (NASDAQ:DXCM) Q4 2023 Earnings Conference Call February 8, 2024 4:30 PM ET Company Participants Sean Christensen - Head of Investor Relations Kevin Sayer - Chairman, President, and Chief Executive Officer Jereme Sylvain - Chief Financial Officer Conference Call Participants Robbie Marcus - JPMorgan Chase and Company Danielle Antalffy - UBS Larry Biegelsen - Wells Fargo Securities Mathew Blackman - Stifel Financial Corp. Marie Thibault - BTIG Jeff Johnson - Robert W. Baird and Company Matt Taylo ...

DexCom (DXCM) reported $1.03 billion in revenue for the quarter ended December 2023, representing a year-over-year increase of 26.9%. EPS of $0.50 for the same period compares to $0.34 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $1.03 billion, representing a surprise of +0.41%. The company delivered an EPS surprise of +16.28%, with the consensus EPS estimate being $0.43.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how ...

• • • • Three Months Ended December 31, Three Months Ended December 31, (In millions) 2023 2022 (In millions, except per share data) 2023 2022 GAAP gross profit $ 656.6 $ 541.3 GAAP net income $ 256.3 $ 91.8 Amortization of intangible assets (1) 7.2 2.4 Amortization of intangible assets (1) 10.1 4.2 Non-GAAP gross profit $ 663.8 $ 543.7 Business transition and related costs (2) 2.0 24.1 Intellectual property litigation costs (3) 13.7 18.4 GAAP operating income $ 216.9 $ 125.4 Income from equity investments ...

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter and fiscal year ended December 31, 2023. Fourth Quarter 2023 Financial Highlights: Revenue grew 27% versus the same quarter of the prior year to $1.03 billion on a reported basis and 26% on an organic1 basis. U.S. revenue growth of 27% and international revenue growth of 27% on a reported basis. International revenue growth was 23% on an organic1 basis. GAAP operating income of $21 ...

DexCom Inc. (DXCM) recently announced the launch of its latest continuous glucose monitoring (CGM) system, Dexcom ONE+. This system is simple to use and lowers the entry hurdle to diabetic technology.The new CGM system is likely to ensure more people gain access to accurate, easy, and real-time glucose monitoring. It aims to deliver a highly effective CGM experience to people treating their type 1 or type 2 diabetes with insulin.Price PerformanceFor the past six months, DXCM’s shares have gained 14.9% compa ...

Revenue and Profit Growth - Revenue for fiscal 2023 reached $3.62 billion, up 24% from 2022[209] - Gross profit for fiscal 2023 was $2.29 billion, up 22% from 2022[209] - Operating income for fiscal 2023 was $597.7 million, up 53% from 2022[209] - Net income for fiscal 2023 was $541.5 million, up 59% from 2022[209] - Net income increased to $541.5 million in 2023 from $341.2 million in 2022, a 58.6% increase[233] Operating and Cash Flow Performance - Operating cash flow for fiscal 2023 was $748.5 million, up 12% from 2022[209] - Positive cash flows from operating activities were $748.5 million for the twelve months ended December 31, 2023[223] - The company expects to generate positive cash flows from operations for the foreseeable future[223] Cost and Expense Analysis - Cost of sales increased by 30% to $1.33 billion in fiscal 2023, representing 37% of revenue[212] - Research and development expenses increased by 4% to $505.8 million in fiscal 2023, representing 14% of revenue[212] - Selling, general, and administrative expenses increased by 18% to $1.19 billion in fiscal 2023, representing 33% of revenue[212] - Research and development expenses increased by $33.7 million, primarily due to higher headcount, partially offset by $15.9 million lower third-party and consulting fees[219] - Selling, general, and administrative expenses increased by $88.8 million due to higher headcount, $37.8 million in legal expenses related to a patent lawsuit, and $36.6 million in advertising and marketing costs[219] Cash and Liquidity Position - The company ended fiscal 2023 with $2.72 billion in cash, cash equivalents, and short-term marketable securities[209] - Cash, cash equivalents, and short-term marketable securities totaled $2.72 billion as of December 31, 2023, with $2.54 billion (93%) located in the United States[223] - The company has a working capital ratio of 2.84 and a quick ratio of 2.38, indicating strong liquidity to cover short-term liabilities[224] Capital Expenditures and Investments - Capital expenditures for manufacturing facilities in Malaysia and Ireland are expected to increase significantly over the next year[224] - Capital expenditures decreased to $236.6 million in 2023 from $364.8 million in 2022, a 35.1% decrease[233] - Proceeds from issuance of senior convertible notes increased to $1.23 billion in 2023 from $22.5 million in 2022, a significant increase[233] - Purchases of treasury stock decreased to $688.7 million in 2023 from $557.7 million in 2022, a 23.5% increase[233] Revenue Drivers and Product Mix - Revenue increased primarily due to higher sales volume of disposable sensors, driven by global customer base growth, with disposable sensor and other revenue comprising 90% of total revenue in 2023, up from 87% in 2022[219] - Gross profit margin decreased in 2023 due to higher amortization of intangible assets and changes in product and channel mix[219] Other Income and Non-Cash Adjustments - Other income increased by $111.2 million, driven by higher interest and dividend income from cash, cash equivalents, and marketable securities[219] - Net non-cash adjustments decreased to $203.8 million in 2023 from $301.6 million in 2022, a 32.4% decrease[233] Risk Management and Financial Instruments - The company has no material exposure to interest rate risk due to the short-term nature of its investments[234] - The 2023 Warrants could have a dilutive effect on earnings per share if the stock price exceeds the strike price[235] - The company is exposed to foreign currency exchange risk, particularly with the Australian Dollar, British Pound, Canadian Dollar, Euro, and Malaysian Ringgit[236] - Foreign currency forward contracts are used to hedge monetary assets and liabilities denominated in foreign currencies, with gains and losses included in other income (expense)[236] - The company translates financial statements of international subsidiaries using end-of-period exchange rates for assets and liabilities and average exchange rates for results of operations[236] Future Technology Development - The company plans to develop future generations of technologies focused on improved performance, convenience, and intelligent insulin administration[198]

DexCom, Inc. (DXCM) is scheduled to release fourth-quarter 2023 results on Feb 8, after the closing bell. In the last reported quarter, the company’s earnings beat estimates by 47.06%.The bottom line also outpaced the consensus mark in each of the trailing four quarters, delivering an average surprise of 36.43%.Q4 EstimatesCurrently, the Zacks Consensus Estimate for DexCom’s fourth-quarter revenues is pegged at $1.03 billion, indicating growth of 26.4% from the year-ago quarter’s reported figure. The consen ...